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The role of new cytotoxic agents like gemcitabine has not yet been proven in the neoadjuvant settings. We designed a phase II
study to test the feasibility of using gemcitabine and cisplatin before local treatment for stage III non-small cell lung cancer
patients. Patients received three cycles of induction chemotherapy of gemcitabine (1000 mg m
72, days 1, 8, 15) and cisplatin
(90 mg m
72, day 15) every 4 weeks before evaluation for operability. Operable patients underwent radical resection.
Inoperable patients and patients who had incomplete resection received concurrent chemoradiotherapy with daily low dose
cisplatin. All patients who did not progress after local treatment received three more cycles of adjuvant chemotherapy of
gemcitabine and cisplatin. Fifty-two patients received induction treatment. Two patients had complete response and 31 patients
had partial response (response rate 63.5%) after induction chemotherapy. Thirty-six patients (69%) were operable. Eighteen
patients (35%) had their tumours completely resected. Two patients had pathological complete response. Median overall
survival was 19.1 months, projected 1-year survival was 66% and 2-year survival was 34%. Three cycles of gemcitabine and
cisplatin is effective and can be used as induction treatment before surgery for locally advanced non-small cell lung cancer
patients.
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Non-small cell lung cancer (NSCLC) is the leading cause of cancer
death in the world. Most patients are diagnosed with inoperable
disease at the time of presentation. Novel chemotherapeutic agents
have been shown in some studies to increase survival of stage IIIB/
IV patients. However, these patients were cured rarely, if ever, by
current chemotherapeutic agents (Hoffman et al, 2000). On the
other hand, several phase III studies have shown that cisplatin-
containing induction chemotherapy may increase survival rate in
stage IIIA or IIIB locally advanced non-small cell lung cancer
(LAD-NSCLC) patients. Two randomized studies demonstrated
increased survival in stage IIIA NSCLC patients if two to three
cycles of chemotherapy were given before surgery (Rosell et al,
1994; Roth et al, 1994). In inoperable patients, induction with
cisplatin plus vinblastine followed by radiotherapy demonstrated
long-term survival advantage over radiotherapy alone in a
randomized study (Dillman et al, 1996) and was conﬁrmed subse-
quently by an intergroup study (Sause et al, 1995). With the
encouraging effects of novel agents in inoperable NSCLC patients,
it is conceivable that replacing conventional cisplatin combinations
with induction regimens containing new agents may further
improve survival in LAD-NSCLC patients.
Gemcitabine plus cisplatin (GC) is one of the most active regi-
mens in the treatment for stage IIIB/IV NSCLC patients. In phase
II studies, 26–54% stage IIIB/IV NSCLC patients responded to GC
treatment. Good median and 1-year survival have been consistently
observed (Abratt et al, 1997; Crino et al, 1997; Einhorn, 1997;
Shepherd et al, 1997). Three randomized phase III studies demon-
strated the superiority of GC over other chemotherapy regimens
(Cardenal et al, 1999; Crino et al, 1999; Sandler et al, 2000). It is
likely that GC as an induction treatment may further improve
survival in LAD-NSCLC patients. Abratt et al (1997) used GC in
stage IIIB/IV patients delivering cisplatin on day 15 resulted in
good response rate (52%), median survival (13 months) associated
with low haematological toxicity and very few dose modiﬁcations
of either gemcitabine or cisplatin. This schedule seems to be
feasible for induction treatment. Based on these observations, we
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using the GC regimen with a day 15 cisplatin schedule as was used
in the Abratt et al (1997) study as induction chemotherapy.
Local recurrence occurs at high frequencies during follow-up in
patients with LAD-NSCLC (Le Chevalier et al, 1994). In a ran-
domized trial, daily low dose cisplatin (6 mg m
72) as radiation
sensitizer given concurrently with radiotherapy reduced local recur-
rence (Schaake-Koning et al, 1992). Overall survival was increased
in patients who received daily low dose cisplatin (16% vs 2%, 3
year survival). Daily low-dose cisplatin was given concurrently with
radiotherapy in the present study.
PATIENTS AND METHODS
Patients selection
Eligibility criteria included pathologically or cytological proven
LAD-NSCLC (stage IIIA/IIIB) (Mountain, 1986) patients. Both
inoperable and operable patients were allowed to enter the study.
T3, T4 or N2, N3 disease must be documented by any of the
following criteria: direct visualization of invasion by tumour of
carina or bronchus with bronchoscopic examination, pathological
or cytological evidence of N2 or N3 disease, unequivocal radiologi-
cal evidence in computed tomography of chest (such as direct
invasion of tumour to vital organs, bulky and multiple mediastinal
lymph nodes). Mediastinoscopy was not a prerequisite if there were
multiple metastatic lymph nodes and at least one of them was
more than 1.5 cm in diameter in a computed tomography of the
chest. Patients who had supraclavicular lymph nodes metastasis,
pleural or pericardial effusion were excluded from the study.
Patients had to be more than 18 years old and had a World Health
Organization (WHO) performance status of 0–2. There must be at
least one measurable tumour and patient must not have received
any prior cancer treatment. Adequate pulmonary function (FEV1
52.0 L or FEV1 and FVC 550% predicted value) and normal
bone marrow reserve (white blood cell count 54000 mm
73,
neutrophils 51500 mm
73, platelet 5100000 mm
73, haemoglobin
510 g dL
71) and good liver, renal function were required.
Patients with superior sulcus tumour, superior vena cava
syndrome, metabolic complications, serious systemic, neurological,
psychological disease and second malignancies were excluded.
Patients were required to sign informed consent to enter the study.
Treatment plan
Treatment consisted of intravenous infusion of gemcitabine
1000 mg m
72 on days 1, 8, 15 and cisplatin 90 mg m
72 on
day 15, in a 28-day cycle. After three cycles, patients were
restaged and evaluated by computed tomography of the chest
for treatment response and operability. Patients were deemed
inoperable either if they were T4, N3 or M1 or if they were
N2 with multiple levels, bulky size or high mediastinal lymph
node involvement. Patients who were operable underwent thora-
cotomy with curative resection and radical lymph node dissection
at least 3 weeks from the last dose of chemotherapy. Concurrent
chemoradiotherapy was given to patients who were not candi-
dates for curative surgery or if residual tumour was noted
after thoracotomy. Radiotherapy was directed at tumour and
lymphatic chains with at least 1 cm margin at 200 cGy/fr, 5 days
a week, for a total of 5600 cGy. Low dose cisplatin at 6 mg m
72
was given within 30 min before radiotherapy to enhance local
control. Three cycles of adjuvant gemcitabine and cisplatin with
the same dose and schedule as in induction treatment were given
to all patients after local treatment. Treatment was delayed if
either haematological or non-haematological treatment-related
toxicity greater than grade 2 was observed. Patients must have
a leukocytes count of more than 2500 mm
73 on day 15 to
receive gemcitabine and cisplatin treatment.
Evaluation of response and toxicity
Patients were evaluated for treatment response using WHO criteria
after three cycles of induction chemotherapy, after surgery, after
concurrent chemoradiotherapy and at the completion of adjuvant
chemotherapy. All scans with documented response were reviewed
in regular meetings by investigators of two institutions. Toxicity of
the treatment was evaluated using WHO toxicity criteria after every
cycle of chemotherapy, after surgery and after concurrent chemo-
radiotherapy. Patients were followed at least every 3 months after
completion of protocol treatment. Computed tomography of the
chest was performed every 3 months until documented relapse or
progression.
Statistical considerations
Kaplan-Meier method was used for survival estimates at various
time points and their 95% conﬁdence intervals were also presented.
Exploratory univariate analyses were performed. Log-rank tests
were used to compare overall survival curves in patients with
different pre-study factors and treatment related predictive factors.
Thirty-eight evaluable patients will provide a less than 2% possibi-
lity of failing to observe any severe toxicity if the true rate of severe
toxicity exceeded 10%. Thirty-eight evaluable patients will also give
a good 95% conﬁdence interval to conﬁrm the 40% response rate
after three cycles of gemcitabine plus cisplatin treatment in NSCLC
patients. If 25% of accrued patients cannot ﬁnish local treatment
for various reasons, a total of 51 patients were needed in this study.
RESULTS
Patient characteristics
The protocol was approved by Institutional Review Boards. All
patients signed informed consent before entering the study. From
August 1997 to September 1999, 54 patients were accrued. Two
patients were found to have stage IV disease upon review and were
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Table 1 Patient characteristics
Number Percentage
Eligible patients 52
Sex
Men 43 83
Women 9 17
Age, median (range) 66 (32–76)
WHO performance status
06 1 2
14 6 8 8
Histology
Squamous cell 30 58
Adenocarcinoma 14 27
Large cell 2 4
Adenosquamous 1 2
Unclassiﬁed or undifferentiated 5 10
Stage
IIIA 26 50
T3N1M0 1
T1N2M0 3
T2N2M0 9
T3N2M0 13
IIIB 26 50
T4N0M0 4
T4N2M0 3
T2N3M0 8
T3N3M0 6
T4N3M0 5
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ã 2002 The Cancer Research Campaign British Journal of Cancer (2002) 86(2), 190–195excluded. Fifty-two patients were included in this analysis. Patient
demographics are listed in Table 1. Most patients were men with
squamous cell carcinoma histology. Forty-seven patients (90%)
had N2 or N3 (cytological or histological proven or unequivocal
radiographic evidence of contralateral mediastinum or hilar lymph
nodes involvement, patients with supraclavicular or neck lymph
nodes metastasis were excluded) disease. Mediastinoscopic biopsy
was performed on 17 patients, with positive lymph node involve-
ment. All other patients who had clinically N2 or N3 disease had
multiple mediastinal lymph nodes, and at least one of the lymph
nodes measuring more than 1.5 cm in size in a computed tomo-
graphy of the chest. Thoracic surgeons reviewed all of the clinical
and radiological ﬁndings. Forty-eight patients had unresectable
tumours and four patients (one T3N1 and three patients with
T2N2) had resectable tumours.
Induction treatment, local treatment and adjuvant
chemotherapy
The treatment and outcome of patients are summarized in Figure
1. Fifty-two patients completed a total of 148 cycles of induction
chemotherapy. Forty-ﬁve patients (87%) ﬁnished three planned
cycles. Seven patients did not complete chemotherapy. Two
patients died of complications (one hepatitis, one pneumonia).
Two patients refused scheduled chemotherapy. Three patients
progressed during neoadjuvant treatment and were withdrawn.
Forty-eight patients (92%) were evaluated for operability after
induction treatment. Thirty-six patients (69%) were operable and
12 patients (23%) were inoperable after induction chemotherapy.
Among 36 operable patients, ﬁve refused surgery, 31 patients
underwent thoracotomy and lymph node dissection. Eighteen
patients (35%) had their tumours completely resected whereas
complete resections were not possible in 13 (25%) patients. Among
these 13 patients, two were found to have disseminated disease
during surgical exploration and 11 patients had unresectable
localized disease. Eighteen patients received concurrent chemora-
diotherapy as salvage treatment (nine patients after incomplete
resection during surgery plus nine inoperable patients). Only 12
patients completed chemoradiotherapy. Six patients had progres-
sive disease during concurrent chemoradiotherapy.
Among 30 patients who were able to ﬁnish local treatment
(surgery and/or concurrent chemoradiotherapy), 23 (44%) were
able to receive adjuvant chemotherapy. Twenty (38%) of them
completed three cycles of treatment.
Toxicity of treatment
Side effects of induction chemotherapy of 52 patients are listed in
Table 2. Two patients died during induction chemotherapy. One
patient died of reactivation of hepatitis B virus. One patient died of
pneumonia, probably related to chemotherapy. One patient died of
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Eligible patients
n=52
Evaluation for
operability
n=48 [92%]
Complication/refusal
n=4
D=4
Inoperable #
n=12 [23%]
Operable
n=36 [69%]
Incomplete
resection@
n=13 [69%]
Refuse operation
n=5
D=3, A=2
Metastasis
n=2
D=1, A=1
Refuse CCRT
n=2
D=1, A=1
CCRT
n=9
Progression
on CCRT
n=2
D=2
No
adjuvant CT
n=1
D=1
Adjuvant CT
n=6
D=3, A=3
Adjuvant CT
n=14
D=5, A=9
No
Adjuvant CT
n=4
D=2, A=2
Complete
Resection
n=18 [35%]
CCRT
n=9 [17%]
Complete
CCRT
n=5
Progression
on CCRT
n=4
D=4
Adjuvant CT
n=3
D=3
No
adjuvant CT
n=2
D=2
Metastasis
n=3
D=2, A=1
Figure 1 Summary of the treatment and outcome of 52 patients. Abbreviations: N: patient number, D; dead, A; alive, CCRT: concurrent chemoradiother-
apy, CT: chemotherapy. #In 12 inoperable patients, three had metastasis after three cycles of neoadjuvant treatment, nine had only locoregional tumours,
but the tumours did not meet criteria for operation. These nine patients all received concurrent chemoradiotherapy. @In 13 patients who had incomplete
resection, two had metastasis and 11 had unresectable locoregional tumour found during operation.
Table 2 Percentage of patients (n=52) with highest grade of toxicity
during induction chemotherapy
Grade Grade Grade Grade
I II III IV
Neutropenia 17.3 15.4 23.1 5.8
Leukopenia 32.7 23.1 21.2 0.0
Thrombocytopenia 17.3 11.5 11.5 0.0
Anaemia 23.1 32.7 21.2 0.0
Fever 19.2 25.0 0.0 0.0
Skin 15.4 26.9 0.0 0.0
Liver 7.7 3.8 0.0 1.9
Renal 5.8 1.9 0.0 0.0
Infection 0.0 1.9 1.9 0.0
Nausea/vomiting 13.5 42.3 26.9 3.8
Pulmonary 7.7 5.8 0.0 1.9
Mucositis 0.0 5.8 0.0 0.0
Diarrhoea 1.9 3.8 3.8 0.0
Alopecia 7.7 5.8 0.0 0.0
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British Journal of Cancer (2002) 86(2), 190–195 ã 2002 The Cancer Research Campaigninfection after operation. There were no other patients with severe
perioperative morbidity after induction chemotherapy. Side effects
of concurrent chemoradiotherapy included grade III/IV neutropenia
(22/28%), thrombocytopenia (17/28%), mild oesophagitis (44%),
mild radiation pneumonitis (17%) and grade III/IV vomiting (6/
11%). Side effects of adjuvant chemotherapy were similar to neoad-
juvant chemotherapy except that haematological toxicity was higher
in adjuvant chemotherapy (grade 3/4 neutropenia, 35 vs 29%; throm-
bocytopenia 35 vs 12% and anaemia 43 vs 21%).
Treatment delays
The protocol was designed to delay treatment until resolution of
treatment related toxicity instead of modifying the dose of treatment.
In 148 treatment cycles, only in 12 cycles (8%) were the treatment
delayed for more than 7 days. One hundred and four cycles (70%)
were given within 3 days of scheduled dates. For 45 patients who
received three cycles of gemcitabine and cisplatin, three cycles of
chemotherapy were completed between 83 to 109 days (median 91
days). The median time to local treatment in 40 patients who received
either surgery or concurrent chemoradiotherapy was 107 days (range
87 to 169 days). Patients who received three cycles of full dose induc-
tion chemotherapy and surgery or concurrent chemoradiotherapy on
day 99 (three cycles of 28-day cycle plus 14 days of rest before local
treatment) was deﬁned as receiving relative dose intensity of 100%.
Median relative dose intensity of induction chemotherapy given for
patients was 92.3%.
Treatment response, survival and failure pattern
Two patients (3.8%) had clinical complete response after neoadju-
vant chemotherapy. Thirty-one patients (59.6%) had partial
response. Response rate was 63.5% (95% conﬁdence interval
50.4–76.6%). Eleven (21.1%) had stable disease and four had
progressive disease (7.7%). Four patients were not evaluable for
response (two complications, two refusals). Pathological samples
were examined in 31 operated patients. Two patients (4%) had
pathological complete response.
After a median follow-up time of 26.4 months (range 2.8–37.3
months), 33 of 52 patients were dead. Probability of survival was
estimated by Kaplan-Meier method and is shown in Figure 2.
The median overall survival for all patients was 19.1 months
(95% conﬁdence interval 14.9–23.3 months), 1-year survival was
66% and 2-year survival was 34%. Median progression-free survival
was 10.6 months (95% conﬁdence interval 8.4–12.8 months). The
outcomes of all 52 patients are listed in Figure 1. Ten patients
(19%) were progression-free at the time of analysis.
In order to ﬁnd out predictive factors for better survival, subse-
quent survival analysis were performed by dividing patients into
subsets according to different levels of stage, histology, age, oper-
ability after induction treatment, nodal status in pathology
specimen, response after induction, response after local treatment
and time-to-local-treatment. Exploratory Kaplan-Meier estimates
based on subsets of patients were derived and overall survival rates
within the subsets are compared using log-rank test. Three factors
(operable after induction treatment, partial or complete response
after local treatment and short time-to-local-treatment) predicted
for favourable outcomes.
All patients were followed to detect ﬁrst relapse or progression
site. Patients who did not receive any local treatment were not
included in the analysis. The information was available in 32
patients. Twelve patients had locoregional (within surgical or radia-
tion ﬁeld) progression or relapse, 16 patients had distant relapse,
four patients had both locoregional and distant as ﬁrst relapse sites.
Fifteen out of these 32 patients have received adjuvant chemother-
apy. Five had locoregional progression, seven had distant relapse
and three had both locoregional and distant progression.
DISCUSSION
In the current study, three cycles of gemcitabine and cisplatin
induced response in 63% of patients. The toxicities of induction
treatment were acceptable. The major difference in toxicity between
this and prior EORTC study (Van Zandwijk et al, 2000) was in
rates and degrees of thrombocytopenia. There were only 11% of
patients with grade 3 thrombocytopenia in this study. Only 8%
of the cycles were delayed. On the contrary, when cisplatin was
given on day 2, 60% patients had grade 3/4 thrombocytopenia in
46% treatment cycles and the haematological toxicity resulted in
day 15 reduction (23%) and omissions (34%) in many cycles.
The difference in toxicity was due to the different dose and
schedule used in Van Zandwijk et al (2000) study (gemcitabine
1000 mg m
72 on days 1, 8, 15 and cisplatin 100 mg m
72 on
day 2). Our study suggests that current schedule (gemcitabine
1000 mg m
72 on days 1, 8, 15 and cisplatin 90 mg m
72 on day
15) is feasible as induction treatment for LAD-NSCLC patients.
The Southwest Oncology Group reported a mature result of
concurrent cisplatin, etoposide with local irradiation as induction
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Figure 2 (A) Overall survival and (B) progression-free survival curves for 52 patients. Patients at risk are given at the bottom.
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ã 2002 The Cancer Research Campaign British Journal of Cancer (2002) 86(2), 190–195therapy in inoperable stage III NSCLC patients. (Albain et al,
1995). The response rate was 59%. Eighty-ﬁve per cent of patients
were operable after induction treatment. Pathological complete
remission was documented in 8% of patients. Median and 2-year
survivals were 13, 17 months and 37%, 39% for stage IIIA and IIIB
patients, respectively. A Cancer and Leukaemia Group B study used
a cisplatin, vinblastine and 5-ﬂuorouracil with radiotherapy in 41
stage IIIA NSCLC patients. The response rate after concurrent
chemoradiotherapy was 51%. Seventy-four per cent of patients
were able to undergo surgery, 59% were completely resected.
Complete pathological response was noted in 9% of patients.
The median survival was 15.5 months (Strauss et al, 1992). The
results of the current and the aforementioned EORTC study
(Van Zandwijk et al, 2000) suggest that GC regimen has achieved
similar efﬁcacy to cisplatin-based concurrent chemoradiotherapy as
induction treatment in LAD-NSCLC patients. Incorporation of
induction chemotherapy with concurrent chemoradiotherapy
followed by radical surgery in the intensive tri-modal therapy has
been successful in treating LAD-NSCLC patients (Eberhardt et al,
1998; Thomas et al, 1999). However, similar survival rates can be
obtained with bi-modal treatment without surgery (Choy et al,
1998; Vokes et al, 1999). Thus, the beneﬁt of surgery after intensive
chemoradiotherapy remains unclear.
Locoregional tumours, distant, both locoregional and distant
tumours appeared in 37.5, 50 and 12.5% as the ﬁrst site of relapse
in this study. Relapse patterns were analyzed in several studies
previously. First relapse was noted in 11% of locoregional, 61%
distant and 28% both local and distant in the tri-modal approach
(Albain et al, 1995). In patients who received radiotherapy alone or
concurrently with daily low dose cisplatin, the locoregional, distant
and both relapse rates were 45, 36, 19% vs 38, 47, 14% respectively
(Schaake-Koning et al, 1992). These observations suggest that both
systemic and local treatment need to be improved in the future.
Patients with inoperable disease after chemotherapy, who did
not respond to chemotherapy and who had delayed local treatment
time had the worst prognosis in this series. Nine patients who did
not reach operable criteria received concurrent chemoradiotherapy
with daily low dose cisplatin. However, all nine patients in this
series who received concurrent chemoradiotherapy as salvage treat-
ment after they failed to respond to chemotherapy were progressed
and eventually died. Patients who did not respond to induction
chemotherapy may be inherently resistant to radiotherapy. A
current EORTC study accruing larger number of patients using
two cycles of GC plus radiotherapy with daily low dose cisplatin
may be able to conﬁrm this observation (Giaccone, 2000).
One patient in this series died of hepatitis B reactivation during
induction chemotherapy. The hepatitis B virus carrier rate in
Taiwan is around 15%. Hepatitis B reactivations were encountered
frequently in hepatitis B virus carriers undergoing chemotherapy.
Hepatitis B reactivation occurred in 20% of 78 carriers in a
prospective study (Yeo et al, 2000). Two patients developed severe
hepatitis B reactivation in 46 stage IIIB/IV NSCLC patients who
received gemcitabine and oral etoposide (Mok et al, 2000). The
use of steroid in chemotherapy may contribute to hepatitis B reac-
tion. Since the natural histories of hepatitis B reaction in these
patients are diverse, the relation between chemotherapy, steroid
and hepatitis B reactivation are still not clear. The patient in this
study received lamivudine after hepatitis B virus reactivation.
However, this treatment was not always successful (Yeo et al,
1999).
In conclusion, three cycles of gemcitabine and cisplatin has
demonstrated a good response rate in LAD-NSCLC patients. This
regimen can be used in the induction treatment for LAD-NSCLC
patients.
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